dupix beat encourag eylea price
futur unclear stay sidelin
eylea beat increas inventori govern price propos key overhang
eylea beat base increas inventori higher demand remind
investor day eylea inventori extra day inventori matter
howev eylea continu show strong growth post year-over-year vs
ultim cautiou continu growth eylea go base
primarili propos includ index intern price think
eylea revenu could start experi slowdown growth product
approach peak sale affect price side whether
current price environ govern propos manag admit
eylea price modestli neg affect price model
y/i growth
dupix impress await pulmonologist uptak asthma
dupix revenu saw strong surg growth quarter-over-quart
believ attribut least part asthma launch believ
asthma indic like bring revenu even higher product
go forward manag comment allergist previou dupix
usag atop dermat signific part initi prescrib base previous
perform physician survey predict high interest dupix asthma
could move allergist xolair dupix
libtayo launch cscc look toward nsclc
libtayo book us revenu cutan squamou cell
carcinoma cscc interest start although indic small manag
maintain focu nsclc although work suggest crowd market
therapi also believ data enough gain usag
nsclc rather expect overal surviv data requir
maintain hold rate price target believ dupix
strong posit captur meaning share sever asthma market includ
share xolair concern eylea price keep us hold also view oral
corticosteroid depend patient patient segment growth dupix sinc
patient group indic present xolair label
price close busi februari
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
data dupix pediatr adregulatori regulatori decis libtayo advanc csccpdufa date eylea npdr patient w/o date dupix adolesc adpdufa date praluent cardiovascular risk reductionpdufa date praluent first-lin hyperlipidemia figur valuat dcf
free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate figur valuat price-to-earnings
fy producteyleau ex-u ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us ex-u dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option expens sg ex-opt collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand regeneron pharmaceut
